When BALB/c mice were injected with a syngeneic cell line transformed by Abelson murine leukemia virus (A-MuLV), the tumor was usually lethal. In sera from tumor-bearing mice, and at highest levels in sera from mice that reject their tumors, was an antibody that immunoprecipitates a specific protein from [35S]_ methionine-labeled A-MuLV-transformed BALB/c cells. This protein was not the previously characterized A-MuLV-specific protein (P120) but a 50,000-molecular-weight protein (P50). Such sera may also immunoprecipitate P120, but no other protein was reproducibly prepipitated by them. A monoclonal antibody (RA3-2C2) that has been shown to stain normal B-lymphocytes also selectively immunoprecipitated P50. P50 was present in A-MuLV-transformed lymphoid and fibroblastic cells of a variety of mouse strains. One A-MuLV-transformed cell line had a very low P50 level, the L1-2 tumor of C57L origin. This tumor was previously shown to be rejected by C57L mice and is used to produce anti-P120 (anti-AbT) sera. P50 was not a Moloney MuLV protein and was found at low levels in normal cells or cells transformed by agents other than A-MuLV; thus, it was probably a host cell protein whose concentration was selectively accentuated by A-MuLV transformation. P50 was phosphorylated and, by using indirect immunofluorescence, anti-P50 serum stained live A-MuLV-transformed cells. The protein was not glycosylated and did not label by lactoperoxidase-catalyzed iodination. Thus, P50 was very like P120 in its cellular localization and properties, but it did not exhibit protein kinase activity in vitro. The selective accentuation of this protein in A-MuLV transformants and its strong antigenicity in syngeneic animals suggest that it is a unique and functionally important protein.
Abelson murine leukemia virus (A-MuLV) can transform certain murine bone marrow cells into continuous cell lines (18) (19) (20) . When these lines are injected into syngeneic mice, the cells usually grow progressively and ultimately kill their host (18) . Only one cell line, the L1-2 line from C57L mice, is reproducibly rejected by its host, and after multiple challenges animals make antisera that recognize the A-MuLV protein (28) . In the prototype A-MuLV strain, the viral protein is called P120 and is the only known product of the viral genome (15, 29 (13) , Sp2/ 0, a nonproducer variant of the P3/X63Ag8 myeloma (7) ; and RLd1, a BALB/c radiation-induced T-cell leukemia (21) .
The following cell lines of C57L/J origin were used: L1-2, an A-MuLV-transformed lymphoid cell line (28) ; and L691, a radiation-induced leukemia (1) .
The following cell lines of NIH/3T3 derivation were duced tumors. Anti-P120 antibodies were obtained from C57L/J mice that had rejected the syngeneic Ll- Labeled cells were washed in phosphate-buffered saline, and the pellet of cells was extracted into 5 ml of lysis buffer (10 mM NaH2PO4-Na2HPO4, pH 7.5; 100 mM NaCl; 1% Triton X-100, 0.5% sodium deoxycholate; 0.1% sodium dodecyl sulfate) at 0°C and clarified at 150,000 x g for 2 to 3 h as previously described (29) . Fractions of 0.5 to 1 ml of cell lysate were immunoprecipitated with normal or immune serum. Antigen-antibody complexes were collected by binding to Staphylococcus aureus (6) . Sodium dodecyl sulfatepolyacrylamide gel electrophoresis was performed on the discontinuous stacking system of Laemmli (9) .
Membrane immunofluorescence. All sera and media employed were filtered through 0.2-,um filters. (3) . Certain batches of sera and RA3-2C2 immunoprecipitate a single protein band; for these cases protein digestion was performed directly after immunoprecipitation of the proteins. S. aureus V-8 enzyme was added to the immunoprecipitated protein and incubated at 37°C for 1 h. The reaction was stopped by adding 2x sample buffer and boiling for 2 min. Samples were then analyzed by electrophoresis through 10% polyacrylamide-sodium dodecyl sulfate gels as described above.
RESULTS
Subcutaneous injection of 5 x 104 2M3/M cells (an A-MuLV-transformed, producer cell line) into syngeneic BALB/c mice produced a 95 to 100% tumor take within 10 to 12 days, which was usually lethal within another 20 to 30 days. Sera taken at a late stage of tumor development from some of these mice could immunoprecipitate a 50,000-molecular-weight protein (P50) from lysates of [35S]methionine-labeled 2M3/M cells (results with sera from 21 individual mice are shown in Fig. 1 ). Because the P50 happens to migrate at the leading edge of a large band of mouse immunoglobulin, its migration rate often seems slightly variable. By examining stained gels, it is evident that the variability is a consequence of varying amounts of immunoglobulin. Fig. 3 ) and A2 formation, were examined for the presence of -d data). The amount of P50 detected P50. They were: RL1, a radiation-induced Tmnd A2 was significantly lower than cell leukemia of BALB/c origin (1); 70Z, a chem-[uLV-induced lymphoid lines tested, ically induced pre-B lymphoid cell line (13); ich higher than in uninfected NIH/ Sp2/0, a nonproducer variant of the mouse myeloma P3/X63Ag8 (7); and L-691, a radiationinduced T-cell leukemia of C57L mice (1). All of these lines gave rise to a very faint band of P50 --, + that was detected on autoradiograms after a very long exposure (Fig. 4) Characterization of P50. To test whether P50 is a phosphoprotein, 2M3 cells were labeled for 5 h with 32PO4, and a cell lysate was prepared. TB serum immunoprecipitated a labeled 50,000-molecular-weight protein from the lysate as well as the A-MuLV P120 (Fig. 5, lane c) . The P120 phosphorylated A-MuLV protein was also detected when this cell lysate was immunoprecipitated with anti-AbT serum (lane b). No phosphoproteins could be detected when normal serum was used (lane a). Labeling the same cells with [3H]leucine and immunoprecipitation with the same sera showed marker bands of P120 and P50 (Fig. 5) .
To determine whether determinants of P50 (26) . If P50 were a glycoprotein, such treatment should change its electrophoretic mobility. No change, however, was evident in the mobility of P50 after such treatment (Fig. 7, lanes a and b) . The experiment was internally controlled by the increased mobility of Pr8Oenv of M-MuLV after treatment (Fig. 7, lanes a and b) . Thus, although P50 is a membrane protein, it is apparently not glycosylated. In its surface localization, phosphorylation, and lack of glycosylation, P50 is like the AMuLV P120 (28) .
Because P50 is expressed on the cell surface, it seemed possible that it could be labeled by lactoperoxidase-catalyzed iodination. When 2M3/M cells were labeled in this way, however, the only iodinated protein that could be detected was the viral gp7O (Fig. 7, lanes c and d) . With 2M3 cells, labeling of P50 was also not detectable. P50 could be iodinated when 2M3/M cells were labeled with Bolton-Hunter reagent (Fig.  7 , lanes e and f). Under these conditions P120 and Pr80env were also iodinated. This reagent penetrates into cells and reacts rapidly with free amino acid groups.
Antisera that precipitate P50. The TB sera used in the studies described above were not the only sera that precipitated P50. Some (2 of 80) BALB/c mice rejected the syngeneic A-MuLVinduced tumor, 2M3/M, and became immune to further challenge: their sera contained high titers of antibody that precipitated P50 from 2M3/M cells, but not L1-2 cells (Fig. 8, lanes c) . Also, certain anti-P120 antibody preparations made in C57L mice (28) have anti-P50 activity. More importantly, however, antibodies from quite different sources also precipitated P50. One highly active anti-P50 serum was the monoclonal antibody RA3-2C2 derived by immunizing rats with murine A-MuLV-induced tumor cells (Coffman and Weissman, in preparation).
This monoclonal antibody was shown to stain all B-lymphocytes, but not thymocytes. The antibody precipitated a 50,000-molecular-weight protein from 2M3/M cells, but no detectable protein from L1-2 cells (Fig. 8, lanes d) .
To examine whether RA3-2C2 actually reacted with the same protein as did TB sera, the P50 bands precipitated by the sera were analyzed by partial protease digestion and electrophoresis (Fig. 9) . There was complete identity of partial cleavage products (lanes b and d) , and the protein precipitated by serum from BALB/ c mice that had rejected tumors also gave the J. (27) .
A striking coincidence in our data is that the one A-MuLV-induced tumor that is rejected by syngeneic mice is L1-2 (28) 
